- Home
- ATOS vs PGP Comparison
ATOS vs PGP Comparison
Compare ATOS & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- PGP
- Stock Information
- Founded
- ATOS 2009
- PGP 2003
- Country
- ATOS United States
- PGP United States
- Employees
- ATOS N/A
- PGP N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- PGP Finance Companies
- Sector
- ATOS Health Care
- PGP Finance
- Exchange
- ATOS Nasdaq
- PGP Nasdaq
- Market Cap
- ATOS 106.9M
- PGP 99.4M
- IPO Year
- ATOS 2012
- PGP N/A
- Fundamental
- Price
- ATOS $0.77
- PGP $8.41
- Analyst Decision
- ATOS Strong Buy
- PGP
- Analyst Count
- ATOS 3
- PGP 0
- Target Price
- ATOS $6.25
- PGP N/A
- AVG Volume (30 Days)
- ATOS 539.9K
- PGP 39.8K
- Earning Date
- ATOS 11-12-2025
- PGP 01-01-0001
- Dividend Yield
- ATOS N/A
- PGP 10.84%
- EPS Growth
- ATOS N/A
- PGP N/A
- EPS
- ATOS N/A
- PGP N/A
- Revenue
- ATOS N/A
- PGP N/A
- Revenue This Year
- ATOS N/A
- PGP N/A
- Revenue Next Year
- ATOS N/A
- PGP N/A
- P/E Ratio
- ATOS N/A
- PGP N/A
- Revenue Growth
- ATOS N/A
- PGP N/A
- 52 Week Low
- ATOS $0.55
- PGP $5.83
- 52 Week High
- ATOS $1.36
- PGP $7.81
- Technical
- Relative Strength Index (RSI)
- ATOS 34.80
- PGP 35.73
- Support Level
- ATOS $0.77
- PGP $8.45
- Resistance Level
- ATOS $0.85
- PGP $8.67
- Average True Range (ATR)
- ATOS 0.05
- PGP 0.15
- MACD
- ATOS -0.01
- PGP -0.04
- Stochastic Oscillator
- ATOS 18.62
- PGP 8.79
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.